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Abstract
Xanthurenic acid (XA) is a metabolite of the tryptophan oxidation pathway through kynurenine and 3-hydroxykynurenine.
XA was until now considered as a detoxification compound and dead-end product reducing accumulation of reactive
radical species. Apart from a specific role for XA in the signaling cascade resulting in gamete maturation in mosquitoes,
nothing was known about its functions in other species including mammals. Based upon XA distribution, transport,
accumulation and release in the rat brain, we have recently suggested that XA may potentially be involved in
neurotransmission/neuromodulation, assuming that neurons presumably express specific XA receptors. Recently, it has
been shown that XA could act as a positive allosteric ligand for class II metabotropic glutamate receptors. This finding
reinforces the proposed signaling role of XA in brain. Our present results provide several lines of evidence in favor of the
existence of specific receptors for XA in the brain. First, binding experiments combined with autoradiography and time-
course analysis led to the characterization of XA binding sites in the rat brain. Second, specific kinetic and pharmacological
properties exhibited by these binding sites are in favor of G-protein-coupled receptors (GPCR). Finally, in patch-clamp and
calcium imaging experiments using NCB-20 cells that do not express glutamate-induced calcium signals, XA elicited specific
responses involving activation of cationic channels and increases in intracellular Ca2+ concentration. Altogether, these
results suggest that XA, acting through a GPCR-induced cationic channel modulatory mechanism, may exert excitatory
functions in various brain neuronal pathways.
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Introduction
In the brain, tryptophan is the precursor of many neuroactive
compounds generated via different biochemical pathways [1]. The
major part of tryptophan degradation is through oxidation via the
kynurenine route that leads to the production of several
neuroactive intermediates, either neurotoxic or neuroprotective
[2]. XA comes from the transamination of 3-hydroxykynurenine
formed from kynurenine by a specific hydroxylase, while
kynurenic acid is the direct transamination product of kynurenine.
Thus, XA and kynurenic acid are closely structurally related but
possess very different biological roles. However the properties of
XA in the brain remain elusive. Kynurenic acid modulates
NMDA and a7 nicotinic receptor activities and possesses
inhibitory properties, while other kynurenine pathway intermedi-
ates like quinolinic acid is considered to be involved in brain
inflammatory diseases via its neurotoxic effects [3–5]. Two
compounds, 3-hydroxykynurenine and 3-hydroxyanthranilic acid,
are considered as free radical generators, and the deleterious
accumulation of the former substance is thought to be reduced by
its transformation into XA [6]. Apart from its involvement in
detoxification processes, no specific or neuromodulatory function
has until now been identified for XA in the brain. It is present in
blood and urine at concentrations of 0.7 and 5–10 mM respec-
tively, but is also heterogeneously distributed in brain tissue at an
average concentration of 1 mM [7]. This XA concentration can be
modified by peripheral administration of this substance that
apparently penetrates the brain freely [7,8].
Up to now, only four different types of information are available
concerning XA roles in various experimental models. First, it has
been reported that XA possesses some toxicity in senile cataract
and certain infectious diseases, and leads to apoptotic-like cell
death in various cell cultures at a concentration of 10 mM [9,10].
Second, XA seems to trigger gametogenesis of the malaria parasite
in mosquito blood via a mechanism that involves cGMP-
dependent protein kinase and intracellular Ca2+ increases [11].
Third, kynurenine metabolites including possibly XA, have been
implicated in the pathophysiology of several neurodegenerative
disorders, where inflammatory and aberrant immunological
processes are observed [12]. Finally, the presence of XA in the
mammalian brain, its distribution, transport and release have led
to the idea that this substance could be involved in some signaling
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pathways, adding XA to the list of neuroactive substances derived
from the kynurenine pathway [7]. Recently, XA has been
identified as a selective endogenous Group II (mGlu 2 and 3)
metabotropic glutamate receptor ligand in vitro and has been
found to mimic the in vivo effects on sensory inhibition in the
thalamus afforded by other Group II mGlu receptor agonists [13].
The present study generated original and key results showing that
XA binds to brain receptors whose kinetics, distribution and
pharmacology are specific. When stimulated by XA or synthetic
related ligands, differentiated neuroblastoma cells exhibited an
excitatory response that led to cytosolic calcium ion increase.
Altogether, the data described herein strongly support a neuro-
transmitter/neuromodulator role for XA in the brain.
Materials and Methods
Xanthurenic acid, kynurenic acid, L-kynurenine, 3-OH-DL-
kynurenine, 5-OH-tryptophan, picolinic acid and 3-OH-anthra-
nilic acid were purchased from Sigma-Aldrich (Saint-Quentin,
France). [3H]-XA was obtained from Amersham (Cardiff, UK; 38
Ci/mmole). Radiochemical purity (97.9%) was evaluated by
HPLC with a gradient of 0.1% trifluoroacetic acid in water/
0.1% trifluoroacetic acid in acetonitrile on a Betabasic C18
column (particle size 5 mm). The material co-chromatographs with
commercially available material in the above chromatographic
system and the mass spectra were consistent with the proposed
structure and a non-labeled reference (Amersham specifications).
Synthesis of Xanthurenic Analogues
4-hydroxyquinoline-2-carboxylic acid analogues (NCS-482,
XT-21 and NCS-486) were synthesized in the laboratory of Dr
J.J. Bourguignon. Cyclocondensation of commercially available
ortho-methoxy anilines 1a,b (Figure S1) with dimethyl acetylene
dicarboxylate followed by cyclization under thermal condition
furnished the substituted ortho–methoxy quinolines 2a, b (Figure
S1) as described in the literature [14]. The 6-bromo derivative (2b)
was submitted to a palladium–catalyzed reaction with phenyl-
boronic acid to give 2c (Figure S1) after purification on flash
chromatography [15]. Deprotection of the methoxy group was
achieved with BBr3. Finally carboxylic acid 3a and 3b (NCS-482
and XT-21, respectively; Figure S1) were obtained after hydrolysis
of the ester group in a solution of potassium iodide in 95%
phosphoric acid [16].
NCS-486 was prepared in a two step reaction starting from
readily available methyl-8-nitro-4-oxo 1,4 dihydroquinoline 2-
carboxylate [17]. Reduction of the nitro group was accomplished
by a catalytic hydrogenation. Hydrolysis of the methyl ester was
performed as previously described [16]. The structures of XA
analogues were confirmed by NMR analysis.
Animals
Adult male albino Wistar rats weighing 350 to 400 g, bred in
the Faculty of Medicine (Strasbourg, France) were used for
experiments. The rats were housed in individual plastic cages
(40 cm ? 25 cm ? 25 cm) on a standard 7:00 to 19:00 h light/dark
cycle with free access to food and water. Procedures involving
animals and their care were conducted in compliance with a
European Communities Council Directive (86/609/EEC) and
under the supervision of authorized investigators. In addition, all
of the protocols were reviewed and approved by the Alsace Head
Office of the French Department of Veterinary and Public Health
Guide for the Care and Use of Laboratory Animals with the
agreement number 67–186.
Crude Synaptosomal Membrane Fraction from Rat Brain
Brains were rapidly extracted from adult male Wistar rats killed
by decapitation after being stunned. All the following procedures
were done with buffers cooled at 0uC. Brains were homogenized
with a motor driven Teflon/glass apparatus in 10 vol (W/V) of
sucrose 0.32 M containing potassium phosphate buffer pH 7.2
and 2 mM EDTA. After centrifugation at 1,500 g for 10 min to
remove the crude nuclear fraction, the supernatant was spun at
35,000 g for 20 min. The pellet obtained was resuspended in lysis
buffer (2 mM EDTA/water pH 6.0 at 0uC, spun at 100,000 g for
20 min). After washing the pellet with potassium phosphate buffer
50 mM, pH 6.0, the crude membrane fraction was directly used
for further experiments or stored at 280uC.
Cell Culture Preparations
NCB-20 cells are a hybrid between mouse neuroblastoma
N18TG2 and Chinese hamster embryonic day 18 brain cells,
which express many properties characteristic of neurons [18]. The
cell line was obtained from the IGBMC (Institute of Genetic and
Cellular and Molecular Biology, Strasbourg) cell collection. These
cells were cultured essentially as described previously [19,20].
Briefly, cells were plated (30,000 cells/ml) in 35-mm Petri dishes.
Each dish contained 2 ml of Dulbecco’s modified Eagle medium
supplemented with 10% fetal calf serum, penicillin (50 U/ml),
streptomycin (50 mg/ml) and 1 mM dibutyryl adenosine 39, 59-
cyclic monophosphate. Cultures were incubated in a humidified
CO2 (5%) incubator.
Human neuroblastoma cells IMR-32 (ATCC number: CCL-
127) were cultured in minimum essential medium Eagle supple-
mented with 2 mM L-glutamine and Earle’s BSS adjusted to
contain 1.5 g/l sodium bicarbonate, 0.1 mM non-essential amino
acids, 1.0 mM sodium pyruvate and 10% fetal calf serum.
Cultures were maintained for one week at 37uC in the presence
of CO2 (5%).
Crude Membrane Fractions from Neurons in Culture
Neurons were scraped into potassium phosphate buffer 50 mM,
EDTA 2 mM, pH 6.0 at 0uC. After centrifugation at 2,000 g for
3 min to eliminate nuclei and large fragments, the supernatant was
spun down at 15,000 g for 10 min; the pellet was washed with the
same buffer and directly used for binding experiments.
Binding Experiments
Membranes (from brain or cell cultures) were incubated for
30 min at 0uC in 50 mM Pipes buffer, pH 7.4 in the presence of
[3H]-XA (2 mCi per mmole total XA at various concentrations).
Non-specific binding was determined with 1 mM non-radioactive
XA in the medium. Bound from free ligand was separated by
rapid filtration on 25 mm Whatman GF/B filters and washing
with incubation buffer (363 ml at 0uC). Radioactivity on filters
was measured by liquid scintillation counting.
Distribution of XA Binding on Rat Brain Slices
Once the optimal conditions for binding were ascertained and
preliminary binding kinetics determined, 3 male Wistar rats were
killed by decapitation, the brains rapidly removed, fixed for 60 sec
in 240uC isopentane on dry ice, and brought to 220uC for 1 h
before cutting. The brains were cut into 20 mm sections at 220uC
and then thaw-mounted onto gelatin-coated coverslips. These
were stored at 280uC until autoradiography was performed.
Based on the preliminary binding experiments, the following
conditions were used for [3H]-XA autoradiography. Slides were
preincubated for 15 min at 20uC in 50 mM, pH 7.4 potassium
Brain Xanthurenic Acid Receptors
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phosphate buffer, then incubated for 30 min at 4uC in the same
buffer with 3 mM [3H]-XA (38 Ci/mmol). Non-specific binding
was determined in the presence of 1 mM non-radioactive XA in
the incubation medium. The slides were washed twice for 10 sec in
ice-cold buffer, dipped in deionized water, dried in a stream of
cold air, and opposed to tritium-sensitive film (Amersham) which
was then placed in X-ray cassettes with appropriate [3H]
microscale standards, exposed for 4–7 days, developed, and
analyzed by computer assisted densitometry.
XA-induced [35S]GTP-c-S Binding
The Scintillation Proximity Assay (SPA) of Amersham was used.
[35S]GTP-c-S binding to rat brain membranes was determined in
the presence of 0.5 to 50 mM of XA. Preliminary experiments have
shown that optimum [35S]GTP-c-S binding stimulated by XA was
obtained with 5 mM GDP and 20 mM MgCl2. Brain synapto-
somal membranes were thus incubated in assay buffer (pH 7.4)
containing 20 mM HEPES, 100 mM NaCl, 20 mM MgCl2 with
0.3 nM [35S]GTP-c-S and 5 mM GDP for 30 min at room
temperature. Non-specific binding was determined in the presence
of 200 mM GTP. WGA SPA beads were added and the mixture
was incubated at room temperature for a further 30 min. The
plates were centrifuged at 1,200 g for 5 min and SPA cpm were
determined by scintillation counting.
Electrophysiological Recordings
NCB-20 cells were plated at low density (104 cells/dish) in 35-
mm dishes and differentiated with 1 mM db-cAMP. The culture
medium was replaced twice a week and the cells were used after 5
days in culture. Cells were recorded either in cell-attached or
whole-cell configuration of the patch-clamp technique [21] using
an Axopatch-B200 amplifier (Axon Instruments, CA, USA) in its
voltage-clamp mode. Current signal was low-pass filtered at 1 kHz
before a 2 kHz digitization using the Digidata 1322A card
interface (Axon Instruments, CA, USA) and Pclamp software
(Axon instruments, CA, USA). Junction potentials were calculated
using the routine procedure in the Clampex software (Axon
instruments, CA, USA) and taken into account for current-voltage
(I–V) relationships and reversal potential calculation according to
the recording configuration.
Whole-cell recording. Tight-seals were performed with
pulled pipettes from borosilicate capillaries whose tip resistance
was 2.260.2 MV (n = 20) when filled with high chloride
containing medium (in mM: KCl 125, MgCl2 2, EGTA/K 5.5,
CaCl2 1, HEPES 10, pH=7.2 with KOH). In some experiments,
we also used a low chloride pipette medium of the following
composition (in mM): K-gluconate 122, KCl 3, NaCl 5, MgCl2 2;
EGTA-K 5.5, CaCl2 1, HEPES 10, pH=7.2 with KOH. In the
latter case, pipette resistance was 4.160.1 MV (n = 56). The mean
cell membrane capacitance value obtained was 53.466.3 mF
(n = 132 cells). Isolated NCB-20 cells were selected for recording
and were continuously superfused with a control solution
containing: (mM) NaCl 135, KCl 5, MgCl2 2, CaCl2 0.5, HEPES
10, D-glucose 10, pH adjusted to 7.4 with NaOH. Under these
conditions, the calculated junction potential had a value of 5.2 and
14.4 mV when using high and low chloride-containing pipette
medium respectively.
Cell-attached recording. For cell-attached recording the
pipette was filled with a medium containing (in mM): N-Methyl-D-
Glucamine (NMDG) chloride 140, KCl 1, MgCl2 10, EGTA 5,
TEA-Cl 15, HEPES 10, pH=7.4. To maintain the cell membrane
potential close to zero, the recorded cells were continuously
superfused with a bath solution containing (in mM): KCl 140,
NaCl 1, MgCl2 1, CaCl2 0.5, EGTA-K 1, HEPES 10, D-glucose
10, pH=7.4. The calculated junction potential in these conditions
was 211.4 mV. Drugs were dissolved in DMSO and diluted in
control solutions such that DMSO in the applied solution was
diluted by a factor of at least 104. Drugs were applied to the
recorded cells through a multi-barrel perfusion system, the rapid
solution exchanger RCS-160 (Bio-Logic, Grenoble, France). Each
barrel had a 1 mm inner diameter and the selected tube was
placed about 100 mm from the recorded cell. The first tube was
filled with control solution and was used to maintain a continuous
superfusion of the recorded cell between applications. The selected
tube was placed in front of the cell by axial rotation of calibrated
angles and the application started when the selected tube takes
place in front of the cell. The parameters of the solution exchanger
were set so as a complete solution exchange around the recorded
cell was achieved in about 2 s.
Data were analyzed offline using the clampfit routine of the
Pclamp software package. The given results are means6SEM and
statistical significance of the difference between means was
determined using one way ANOVA followed by Dunnett’s
Multiple Comparison test.
Monitoring of [Ca2+]i Changes
The method of cellular calcium measurement used was as
described previously [22]. Briefly, NCB-20 cells were plated in
glass-bottomed culture dishes and incubated at 37uC for four days.
Cells were loaded with the fluorochrome by incubation in Krebs
medium (in mM: NaCl 145, KCl 2.7, MgCl2 1, CaCl2 1.8, D-
glucose 10, HEPES 10, pH 7.4) containing 10 mM fluo-4 AM and
0.02% pluronic acid F127 for 30 min at 37uC in the dark. Then
the cells were washed with Krebs for 30 min at room temperature
in the dark. All settings of the laser (Argon-Krypton laser, turned
to 488 nm), optical filter (BF 530/30) and microscope (Leica TCS-
SP confocal inverted microscope) as well as data acquisition were
controlled by the LCS (Leica Confocal System) software. Images
were taken using a 256 gray scale with a photomultiplier and the
‘‘glowoverglowunder’’ system (Leica) using a 406 objective, NA
1.2, with an electronic zoom of 2 to 4 fold. The image size was
5126512 pixels and before each measurement, serial sections were
acquired in the vertical axis to choose the equatorial section of the
cells.
Images were recorded at a frequency of 0.1 Hz. Analysis was
performed by defining regions of interest (ROI) in the first image.
Values are expressed as the percentage of fluorescence change
with respect to control and calculated as F/F0 (%) (where F is the
fluorescence intensity at a given time and F0 the basal fluorescence
intensity at the beginning of the experiment).
The cells were continuously superfused with normal Krebs
medium and transiently submitted to the tested drug using a
peristaltic pump with a flow rate of 1 ml/min. For each analyzed
cell, the mean and the standard deviation (SD) of the F/F0 of
fluorescence were measured during 1–2 min before (base line) and
after (signal) drug application and compared. Statistical signifi-
cance of the difference between means was determined using one
way ANOVA followed by Dunnett’s Multiple Comparison Test
for repeated measurements on absolute levels of fluo-4 fluores-
cence [22].
Results
Binding Sites for XA on Brain Synaptosomal Membranes
and on Neuronal Cell Lines
Saturation experiments performed with increasing concentra-
tions of radioactive XA showed the presence of binding site(s) for
this compound on crude synaptic membranes isolated from rat
Brain Xanthurenic Acid Receptors
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brain. Non-specific binding was linear and specific binding was
proportional to protein concentration under our experimental
conditions (data not shown). Optimum pH for specific binding was
about 7.560.3 as determined in Pipes buffer from pH 5.5 to 8.0
(data not shown).
For crude brain synaptosomal membranes, IMR-32 and NCB-
20 neuroblastoma cells, dissociation constant (Kd) values of
respectively 0.74, 0.75 (Bmax 5.260.4 pmoles/mg protein) and
1.30 mM (Bmax 4.860.5 pmoles/mg protein) were obtained (non
linear regression lines with the GraphPad/Prism software,
R2= 0.96; 0.71 and 0.90 respectively). For brain membranes
(Figure 1), a calculated Bmax value of 7.560.4 pmoles/mg protein
was obtained and association (Kon) and dissociation (Koff) rate
constants were determined (pH 7.4 and 0uC). Kon was calculated
according to the following relation: Kon = (Kob-Koff) [L] (Graph-
Pad Prism Program, San Diego, CA). Kob was obtained by
monitoring the amount of [3H]-XA (0.2 mM; 2 mCi/mmole)
specifically bound with time (30 sec to 40 min; 3 experimental
points every minute). Under these conditions, the binding began to
saturate after 3 min (goodness of fits, R2= 0.75) and Kob was
1.44 min21 (GraphPad/Prism program). Koff was determined
under the same conditions in the presence of 1 mM non-
radioactive XA and showed a value of 1.26 min21 (R2 = 0.74).
From these results, the calculated Kd was 1.4 mM which is close to
those obtained using saturation experiments.
Pharmacological Properties of XA Binding Sites
Two approaches were used for screening the pharmacological
properties of XA specific binding. First, we tested at rather high
concentration (200 mM) a battery of putative ligands for these sites.
Among these, glutamate and GABA exhibited very low potency
(Figure 2). The fact that glutamate displaced not more than 10%
of radioactive XA eliminates possible binding of XA on glutamate
receptors under our conditions [13].
Among XA related compounds that were tested for their ability
to displace XA specific binding (Figure 2), kynurenic acid was a
weak competitor (30% displacement at 200 mM concentration),
picolinic and quinolinic acids had much more significant effects
(60% and 40% displacement respectively). For the more powerful
competitor picolinic acid, a dose-dependent displacement of
[3H]XA binding was performed (data not shown) and a mean
IC50 value of 4165 mMwas obtained, indicating its low affinity for
the XA binding sites. Therefore, this screening test revealed the
specificity of XA among the compounds tested.
Secondly, to extend the pharmacological profile of XA, this
compound was tested on high-throughput profile screening which
involved a collection of 75 transmembrane and soluble receptors,
ion channels and monoamine transporters (Cerep, France
Laboratories, Poitiers). XA was tested on these collections of
proteins at 10 mM concentration. No significant competitive
properties of XA were observed on the binding of specific ligands
for each of these proteins (for detailed information on the protein
collection, see the CEREP catalogue at www.cerep.fr/cerep/users.
In particular, XA was found to have no effect on adenosine,
benzodiazepine, dopamine, GABA, canabinoid, histamine, mus-
carinic, opioid, purinergic and serotonin receptors.
Autoradiographic Distribution of XA Binding Sites in the
Rat Brain
Reversible high affinity XA binding (Figure 3 and Table 1)
appeared to be especially localized in the rostral part of the rat
brain, including diencephalic and telencephalic structures (cortex,
hippocampus, striatum, thalamus, olfactory tracts). By contrast,
the mesencephalic region was almost completely devoid of binding
sites, with the exception of dopaminergic mesencephalic nuclei
(A9/A10), but this result is not absolute considering the definition
levels of the image analysis. In the caudal part of the brain, there
Figure 1. Saturation curve showing specific binding of [3H]XA
displaced by 1 mM non-radioactive XA on crude synaptosomal
membranes from rat brain. TB: total binding; NSB: non-specific
binding; SB: specific binding. Non-linear regression lines with GraphPad
Prism Program; R2 = 0.78. Each point is the mean6SD of three
experiments made in triplicate at each concentration. Kd = 0.74 mM;
Bmax = 7.5 pmoles/mg protein.
doi:10.1371/journal.pone.0048553.g001
Figure 2. Effects of amino acid neurotransmitters, selected XA-
related analogues and compounds of the kynurenine pathway
on XA binding sites. Each compound was tested at 200 mM
concentration in the presence of radioactive XA. Displacement of
radioactive XA induced by 200 mM XA was arbitrarily set at 100%. Result
values are the mean of 3 experiments performed in triplicate6SEM.
doi:10.1371/journal.pone.0048553.g002
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was also a low density of sites with the notable exception of
cerebellum (Figure 3 and Table 1). These results highlight the
heterogeneous distribution of XA binding sites in the rat brain, the
richest regions (dorsal hippocampus and caudate nucleus)
expressing about 250 fmoles of sites per mg tissue while some
other regions did not display detectable binding.
XA Stimulates [35S]-GTP-c-S Binding on Rat Brain
Synaptosomal Membranes
Preliminary experiments showed that XA-induced radioactive
GTP binding to rat brain synaptosomal membranes occurred
optimally for GDP and MgCl2 concentrations of 5 mM and
20 mM respectively (Figures 4A and 4B). Using XA concentra-
tions ranging from 0.5 to 50 mM, GTP binds to the membrane
fraction with an EC50 of 2.061.9 mM (Figure 4C).
Electrophysiological Responses Induced by XA in NCB-20
Cells
Our aim in these experiments was to describe a XA cellular
effect mediated by specific receptors differing from that reported
through class II metabotropic glutamate receptors (mGluR2/3)
[13]. The best way for this initial characterization of XA cellular
effects was to use a neuronal preparation that does not express
these mGluR receptor types. Differentiated NCB-20 cells were
chosen because they express a neuronal phenotype [18], do not
express glutamate receptors that increase cellular calcium levels
[23] and exhibit XA binding sites. However, application of this
cellular model is limited to this first identification of XA
neuroactivity, and the active effect of XA should be confirmed
on neurons of different species.
Whole-cell recording of the XA response. XA responses
were recorded from db-cAMP differentiated NCB-20 cells after
5 days of culture. An XA (1 to 30 mM) induced response was
frequent and present in about 71% of the cells tested.
The XA response consisted of an inward current at negative
membrane potentials (Figure 5A and 5B). Figure 5C represents I–
V relationships of the mean peak current amplitude induced by
XA applications in conditions of high or low chloride-containing
pipette medium. In both conditions the mean peak current
amplitude was linear in the potential range tested. Comparable
cellular conductance (Figure 5D) and reversal potential mean
values were obtained at high (3 cells) and low chloride (4 cells)
conditions and corresponded to 11.162.6 and 12.763.2 nS and
23.364.0 and 23.862.5 mV respectively. These results suggest
that the XA-induced current was carried by cationic ions. The XA
activated conductance was dose-dependent (Figure 5E) with an
EC50 of 11.762.2 mM.
Cell-attached recording of the XA response. One ap-
proach to demonstrate the implication of a diffusible second
messenger in G-protein responses is to record a response from a
membrane-patch isolated from the rest of the cell membrane that
is exposed to the agonist stimulation. This was done using the cell-
attached configuration of the patch-clamp technique. The cells
were bathed with a KCl solution (see methods) so as to clamp the
membrane potential of the recorded cell close to zero mV.
Figure 6A illustrates a membrane patch response induced by
application of 10 mM XA to the recorded cell.
Unexpectedly, the cell-attached configuration using NMDG
and Mg2+ as major monovalent and divalent cation ions
respectively revealed a reversal potential (Er) for XA responses
that could change across a large range of potentials during the
same response. Thus, we used a voltage ramp protocol that
allowed us to follow Er time evolution at a frequency of 0.2 Hz. In
the case illustrated in figure 6A, the Er evolved sequentially
(positions 1 to 5 in figure 6A) from an initial value of 29 mV to
levels of about 14, 25, 21 and 226 mV (Figure 6B). I–V curves
Figure 3. Distribution of rat brain XA binding sites. Autoradiogram of sagittal sections of rat brain (lateral 1.90 mm, according to Paxinos and
Watson (1998)), showing in A the distribution of XA binding sites as a pseudo-color image (dark brown/red: +++; brown: ++; yellow: +). 1: cerebellum;
2: cortex; 3: hippocampus; 4: olfactory tracts; 5: striatum; 6: thalamus; 7: mesencephalic dopaminergic nuclei (A9/A10). In the presence of an excess of
non radioactive XA (1 mM), a very faint image can be detected on autoradiographies (B).
doi:10.1371/journal.pone.0048553.g003
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corresponding to each of these levels are given in figure 6D. These
levels were also obtained from the frequency histogram (Figure 6C)
of the reversal potential data given in figure 6B. This frequency
distribution was best fitted with a sum of 5 Gaussians with mean
parameter values of Er1= 223.2, Er2= 29.6, Er3= 0.8,
Er4= 12.6 and Er5= 20.3 mV. However, in the total XA-
responses recorded in these conditions, the five Er levels were
not always present together in a given XA response, but rather as a
combination of a subset. Particularly, levels Er2, Er3 and Er4 were
by far the most frequent. The global Er data mean values (Er1 =
232.264.0, Er2= 213.961.1, Er3= 21.060.6,
Er4= 11.560.8 and Er5= 31.162.0 mV) are illustrated in
figure 6E. These results suggest that XA activated cationic
channels of different selectivity toward K+, NMDG+ and Mg2+
ions.
Pharmacological properties of Xanthurenic responses
using synthetic analogs. Among the synthesized XA analogs,
we selected some of them for their affinity for XA binding sites and
tested their functional properties in patch-clamp experiments.
Three molecules (NCS-486, NCS-482 and XT-21, Figure 7) were
selected for their antagonistic (NCS-486) or agonistic properties
(NCS-482 and XT-21). These three analogs displaced XA binding
with an IC50 of 14, 0.35 and 4.6 mM respectively (Figure 7).
Application of NCS-482 or XT-21 to NCB-20 cells induced
similar responses to XA effects, such that at negative membrane
potentials an inward current was seen (Figure 8A and 8B). XT-21
was by far the most efficient agonist since 5 mM elicited about 2.5
and 1.5 fold more important response amplitudes than 10 mM XA
and 18 mM NCS-482 respectively (Figure 8C).
NCS-486 (20 mM) did not have any effect by itself on NCB-20
cells (Figure 8B; 6 cells tested). However, when co-applied at this
same concentration with 10 mM XA, 5 mM XT-21 or 18 mM
NCS-482, NCS-486, it strongly inhibited the agonist-induced
response such that the current-response was reduced by 88.363.8,
86.165.0 and 88.763.2% respectively (Figure 8D). Like XA,
NCS-482 and XT-21 induced responses were inhibited by the
same compound (NCS-486), and all these compounds (NCS-482,
NCS-486 and XT-21) efficiently displaced [3H]-XA binding.
These data suggest that the compounds used here competed with
the same receptor type and that NCS-486 possesses antagonistic
properties at this XA receptor(s).
Fluo-4 Studies
Effects of XA. Cytosolic Ca2+ concentration of NCB-20 cells
significantly increased during stimulation with XA. The increase
in fluorescence intensity induced by a 6 min application of 10 mM
Table 1. Quantitative autoradiographic densities of binding sites in brain regions.
Brain regions Density of sites (fmoles/mg equivalent tissue) Relative percentage (%)
Dorsal hippocampus 268.565.3 100
Caudate nucleus lat. part 252.064.0 93
Central amygdaloı¨d nucleus 249.465.6 92
Accumbens nucleus lat. part 247.3612.8 91
Pyriform cortex 233.5611.9 86
Parietal cortex 228.263.0 84
Cerebellar lobules 226.067.6 83
Post. medial thalamic nucleus 220.969.0 81
Dorsomedial hypothalamus 220.769.5 81
Cingulate cortex ant. part 219.766.4 81
Prefrontal cortex 219.7614.0 81
Olfactory tracts 221.2610.6 81
Lateral septal nucleus 208.967.2 76
Mediodorsal thalamic nucleus 203.765.1 75
Globus pallidus 183.568.7 67
Medulla oblongata 162.266.6 59
Occipital cortex 160.0637.8 59
Medial septal nucleus 149.4615.1 55
Ventral hippocampus 110.062.2 40
Interpeduncular nucleus 106.862.2 39
Substantia nigra (A9) 104.661.8 38
Dorsal raphe nucleus (B7) 94.167.7 34
Periacqueductal gray matter 94.165.2 34
Ventral tegmental area (A10) 89.865.6 32
Temporal cortex 82.466.8 30
Median raphe nucleus (B8) 70.662.2 25
Results are mean6SD of the quantitative optical density in the autoradiographic trace (Biocom program) by reference to standard autoradiographic scales (Amersham).
Results are mean of 8 to 10 measures in each brain region.
The limit of the signal detection is about 50 fmoles/mg equivalent tissue.
doi:10.1371/journal.pone.0048553.t001
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XA is shown in figure 9A and is represented by a large signal
starting about 1 min after XA application. The intensity of this
signal reached up to 60–80% above basal levels and persisted for
about 5 min before returning to basal levels.
The XA-induced response was dose-dependent (Figure 9B). The
amplitude of the response increased from 1 to 10 mM XA
concentration and reached a mean apparent maximum of about
15763% (p,0.001). This first phase of the dose-response
distribution can be described by the Hill’s equation whose optimal
fit to data points gave an EC50 value of 1.4 mM that is very close to
the EC50s obtained for GTP-c-S (2 mM) and binding (1.3 mM)
experiments. However, higher XA concentrations induced a
partial decrease of the signal. This decrease was statistically
significant and could also be described by the Hill’s equation with
an IC50 value of 18.3 mM. This partial inactivation could be the
result of the well known GPCR arrestin-dependent desensitization
mechanism and/or an inactivation linked to an intrinsic cellular
calcium regulation.
Effect of NCS-486. The effect of the XA receptor antagonist
NCS-486 was studied on about 50 cells from several culture
batches. Solutions containing 100 mM NCS-486 and/or 25 mM
XA were applied to the cells during 5 min intervals as shown in
figure 9C. No fluorescence change was detected in the experi-
ments when the antagonist was applied alone (83.962.7%) or with
XA (86.960.7%). However, after a short washout of 5 min, the
application of XA induced a significant [Ca2+]i increase
(134.966.5%), confirming the antagonistic properties of NCS-
486 (Figure 9C and 9D).
Discussion
We have recently reported a series of specific properties of XA
endogenously present in the rat brain [7]. These results were the
first evidence supporting the existence of a specific role of XA in
neurotransmission and/or in the regulation of neuronal excitabil-
ity. To address an important issue in this domain, the present work
aimed at demonstrating the existence of specific receptors for XA
in the brain. On the basis of kinetic analysis and autoradiographic
studies, we showed the existence of XA binding sites with
heterogeneous distribution in the rat brain. As it has been shown
that XA can bind to mGlu 2/3 receptors, it cannot be excluded
that the autoradioraphic images obtained with radioactive XA
represent in part the mGlu 2/3 receptors. However, the present
images were obtained with the endogenous natural ligand XA
while labeling of mGlu 2/3 was carried out with a synthetic rigid
analogue of glutamate which possesses high affinity for these
receptors [24]. Thus, the autoradiographic images are most
probably a superimposition of mGlu 2/3 receptors with the
present XA receptor. Some brain regions are almost totally devoid
of binding sites. Binding sites appear to be localized on neuronal
Figure 4. XA-induced GTP-c-S binding characteristics. A and B
show the optimal concentration level of GDP and MgCl2 respectively
that induce maximal GTP-c-S binding in the presence of a fixed
concentration of XA (5 mM). C: EC50 of GTP-c-S binding to crude
synaptosomal membranes from rat brain in the presence of increased
XA concentrations from 0.5 to 50 mM. Non-linear fitting using the
GraphPad Prism program, each experimental point was the mean6SEM
of three results obtained in triplicate at each concentration.
doi:10.1371/journal.pone.0048553.g004
Figure 5. Whole cell recording of XA responses from differen-
tiated NCB-20 cells. A and B: Current traces recorded in conditions of
high (A) or low (B) cytoplasmic chloride ([Cl]i) concentrations. XA was
applied to the recorded cells as indicated by the horizontal bars. C:
Mean I–V relationships obtained in conditions of low (filled circles) or
high (open circles) [Cl]i (5 cells in each condition). The dashed and
continuous lines are the zero current level and linear regression to the
data points respectively. Note that the reversal potential of XA
responses did not change (24.8 and 24.4 mV) with cellular chloride
activities and was close to the cationic reversal potential which had a
value of 20.9 and 0.4 mV in conditions of high and low cellular Cl
concentrations respectively. D: mean cellular conductances activated
by XA (20–30 mM) in high (black bar) and low (white bar) Cl
concentrations respectively (mean6SEM, n = 7 cells). E: Dose-response
relationship of XA. The continuous curve is the optimized Hill equation
to the data points. Optimization parameters were EC50 = 11.7 mM,
maximal conductance = 12.5 nS and Hill coefficient = 3.5.
doi:10.1371/journal.pone.0048553.g005
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membranes, but this may not be exclusively the case because the
kynurenine pathway is partly present in astrocytes [25] and
oligodendrocytes [26]. The affinity of these sites for their
endogenous ligand is closely related to the average concentration
of XA present in rat brain tissue [7]. Between the classical amino
acid neurotransmitters GABA and glutamate, only glutamate had
a very weak effect on XA binding suggesting that the contribution
of XA binding to glutamate receptor types in our conditions did
not exceed about 10%. It could be concluded that the present XA
receptor is not glutamate-sensitive and is most probably an
original XA receptor.
Furthermore, some structural synthetic analogues of XA also
exhibit affinity for XA binding sites, contrasting with the low
affinity of most of the kynurenine pathway intermediates.
Screening for possible interactions of XA on a collection of 75
other neuronal membrane receptors is also in favor of the
existence of XA specific binding sites. Interference with possible
glutamate receptors was not tested because of the very low effect of
glutamate on XA specific binding. In addition, the electrophys-
iological responses induced by XA on NCB-20 neurons that show
no glutamate-induced stimulation eliminate potential glutamate
receptor contributions. Overall, the results reported in this paper
lend support to the idea that the XA binding sites are neuronal
receptor sites that mediate excitatory responses in brain by
involving G proteins. The XA-induced GTP-c-S binding at
optimal MgCl2 and GDP concentrations with an EC50 close to the
Kd of XA for binding sites is an important indication in favor of
this assumption. In addition, electrophysiological results using
patch-clamp experiments in the cell-attached configuration
showed the involvement of cytosolic second messengers in the
NCB-20 responses to XA that strongly suggest the involvement of
G protein(s).
However, the present XA activated G-protein coupled recep-
tor(s) remains to be identified, together with its possible existence
in other tissues, particularly in the human brain. Recently, it has
been suggested that XA could be a ligand of class II metabotropic
glutamate receptors and based on in vivo recording of rat
ventrobasal thalamic neuronal activity the authors suggest that
XA could act as an allosteric agonist compound on this class II
mGluR [13]. Our autoradiographic results on tissue XA binding
cannot exclude cross-binding to mGluR II. However, using
differentiated NCB-20 cells which do not express glutamate-
inducible intracellular calcium responses [23], we clearly show in
the present study that XA is able to induce cytosolic calcium
increases. Moreover, the XA-induced functional effects reported
here were obtained from cells under continuous superfusion and
XA was applied alone, suggesting an agonist rather than an
allosteric effect of XA. Furthermore, class II mGluR specific
agonists reduce synaptic activity by potassium channel activation
[27]. On the contrary, our results revealed a probable excitatory
effect of XA through the activation of cationic channels and
intracellular calcium increases. All these results strongly suggest
Figure 6. Reversal potential of XA-induced responses in the cell-attached configuration. The membrane patch was recorded in the
NMDG-Cl condition and stimulated by a ramp potential protocol (270 to 90 mV, 600 ms duration) at a frequency of 0.2 Hz. A: Membrane patch
current traces recorded at different membrane potentials (Vm) as indicated in the figure. The colored vertical lines 1 to 5 indicate the different steps
of the Er variations. The dashed lines represent the zero current level for each current trace. B: Time evolution of the Er value obtained by the ramp
potential stimulation protocol during the XA response given in A (control current was subtracted). C: Frequency histogram of the Er values obtained
during the XA response. The distribution was best fitted by the sum of 5 Gaussians with parameter values of: mean Er =223.2, 29.6, 0.8, 12.6 and
20.3 mV, standard deviation s= 6.3, 2.1, 3.6, 2.1 and 2.3 and amplitude = 3.0, 5.6, 8.4, 23.8 and 20.4 respectively. D: I–V relationship of the XA-induced
current recorded at the times indicated by numbers 1 to 5 in A. The reversal potential for each I–V curve is indicated by dashed vertical lines (1 to 5).
E: Mean data (6 SEM) of the reversal potential classes (Er1 to Er5) obtained from the different XA responses. In parenthesis are given the number of
time a given Er class was observed overall the XA responses. ***: p,0.001.
doi:10.1371/journal.pone.0048553.g006
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that the XA cellular responses we describe here were not mediated
by metabotropic glutamate receptors but by distinct receptor(s)
which remain to be identified.
Plasma membrane effectors of NCB-20 cells stimulated by XA
receptor(s) activation are cationic channels of different selectivity,
as revealed by the use of the cell-attached recording mode and
NMDG+/Mg2+ pipette medium. Whether this multiple channel
selectivity originates from dynamic changes in channel selectivity
[28,29] and/or different channel structures remains to be studied.
Whatever the molecular mechanism involved in this channel
selectivity or diversity, considering that some XA-activated TRP
channels seem to be permeable to divalent cations, they are
probably members of the TRPM and/or TRPV channel
subfamilies [29–31]. Their activation evoked cytosolic Ca2+
increase, as evidenced by our experiments using Fluo-4 calcium
probes. This cellular Ca2+ increase may arise from calcium influx
and may include a participation of voltage-dependent Ca2+
channels. However, cellular Ca2+-store mobilization cannot be
excluded. Interestingly, the depolarizing effect resulting from
cationic channel activation and the rise in cellular free calcium
observed confer an evident excitatory role for XA and suggest that
it may facilitate neurotransmitter release.
XA effects were registered at micromolar concentrations which
are within the range of the calculated Kd for the binding site. In
addition, the effect of synthetic related XA structural analogues
suggests a pharmacological specificity of the XA binding/receptor
site which is not shared by the natural kynurenine intermediates so
far tested. Among the synthetic compounds, NCS-486 appears to
display antagonistic properties. These types of synthetic XA
Figure 7. Structural representation of XA and selected analogs
and their IC50 of [
3H]XA binding displacement. XA analogs were
selected for their agonist (NCS-482 and XT-21) or antagonist (NCS-486)
properties.
doi:10.1371/journal.pone.0048553.g007
Figure 8. Pharmacological characteristics of XA responses recorded in the cell-attached mode from differentiated NCB-20 cells. A
and B: Agonistic action of XT-21 and NCS-482, and inhibition by NCS-486 of XA, XT-21 and NCS-482 responses. Note the absence of effect of NCS-486
when applied alone (B). Horizontal bars represent periods of drug application as indicated. C: Statistical data of mean response amplitude (6 SEM)
obtained with XA, XT-21 and NCS-482 (6, 7 and 4 cells respectively) applied at concentrations as indicated. D: Inhibition of the agonist-induced
responses by NCS-486 20 mM (12 cells). The mean of agonist responses (control) was set at 100%.
doi:10.1371/journal.pone.0048553.g008
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related analogues could open new avenues for the synthesis of
pharmacological tools and potential therapeutic agents, similar to
those developed for kynurenic acid [12].
Finally, the list of human diseases showing abnormal kynuren-
ine pathway metabolism is extensive and diverse [12]. In this
context, we propose that the controlled and balanced actions of
kynurenic acid and of its related analogue XA participate in the
control of inhibitory/excitatory phenomenon in brain, via the
crucial regulation of the activity of kynurenine 3-hydroxylase. The
deregulation of these dual functions via distinct receptors could be
at the base of pathological neurological situations in which the
implication of the kynurenine pathway has been suggested.
To summarize, the non-uniform cerebral distribution, kinetic
parameters and specific pharmacology of XA binding sites strongly
suggest the expression of specific XA receptors in the rat brain,
most probably of the GPCR type. These findings suggest a novel
function for XA in brain. However, several other methodological
approaches are needed to better understand the status of XA
among brain kynurenine pathway derivatives, particularly its
possible implication in diseases involving tryptophan metabolism
oxidative circuits [1,32–34].
Supporting Information
Figure S1 Synthesis of the XA analogues NCS-482 and
XT-21.
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Figure 9. XA-induced intracellular Ca2+ increase in differentiated NCB-20 cells. A: Time course of intracellular Ca2+ increase detected by
fluo-4 probe. The presence of XA 10 mM induced an increase of fluorescence intensity. B: Dose-effect of XA-induced response. Data point distribution
was biphasic and could be described by activation and partial inactivating phases (green and dark red curves respectively obtained by fitting with the
Hill’s equation using optimal parameters as indicated in the figure). C: NCS-486 antagonism of the XA-induced cellular calcium response. NCS-486
(100 mM) applied alone or in combination with XA 25 mM did not modify significantly the intracellular Ca2+ concentration. After 5 min of washout of
the antagonist, XA 25 mM induced a typical increase of fluorescence intensity. D: Statistical data of the fluorescence intensity obtained in the
presence or absence of XA and/or NCS-486. Results are means6SD obtained from 15 to 50 cells in each condition. Horizontal bar indicates the period
of drug application. ***: p,0.001.
doi:10.1371/journal.pone.0048553.g009
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